Showing results (261-270 of 368) with videos related to

Sort By:
Pageof 37
JAMA Cardiology|June 4, 2025
Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical TrialKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
European Journal of Heart Failure|February 17, 2021
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trialJawad H Butt, Jose C Nicolau, Subodh Verma, et al.
Journal of the American Society of Nephrology : JASN|December 11, 2023
Empagliflozin in Heart Failure: Regional Nephron Sodium Handling EffectsVeena S Rao, Juan B Ivey-Miranda, Zachary L Cox, et al.
JACC. Advances|June 27, 2025
Dapagliflozin's Association With Cardiorenal Outcomes and Apolipoprotein M Levels in HFrEF Patients: Insights From DEFINE-HFAndrew J Sauer, Joycie Chang, Zhuxuan Fu, et al.
JACC. Heart Failure|April 28, 2022
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF TrialSu Ern Yeoh, Kieran F Docherty, Pardeep S Jhund, et al.
Diabetes Care|August 7, 2015
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes AssociationCaroline S Fox, Sherita Hill Golden, Cheryl Anderson, et al.
Circulation|December 28, 2018
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 TrialBenjamin M Scirica, Erin A Bohula, Jamie P Dwyer, et al.
European Journal of Heart Failure|July 17, 2024
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVERAmr Abdin, Toru Kondo, Michael Böhm, et al.
The Journal of Clinical Endocrinology and Metabolism|May 6, 2004
Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trialAndrew R Hoffman, Joyce E Kuntze, Joyce Baptista, et al.
American Heart Journal|December 3, 2014
Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke TrialCatherine M Viscoli, Lawrence M Brass, Antonio Carolei, et al.
Pageof 37